Printer Friendly

PHASE I CLINICAL TRIALS OF MIKASOME INITIATED BY VESTAR; LIPOSOMAL FORMULATION OF ANTIBIOTIC MAY COMBAT RESISTANT TB

 SAN DIMAS, Calif., July 7 /PRNewswire/ -- Vestar, Inc. (NASDAQ: VSTR) announced today the start of Phase I clinical trials of MiKasome, the company's liposomal formulation of the antibiotic amikacin. Preclinical data from tuberculosis and mycobacterium avium infection models resistant to traditional chemotherapeutics have demonstrated that MiKasome produces a significant killing effect.
 "Phase I trials represent the first opportunity to explore in humans the profile we've seen in animals, although preclinical success does not guarantee success in humans. Our Phase I trials will carefully analyze the safety and pharmacokinetics of MiKasome," said Roger J. Crossley, M.D., chairman, CEO and president of Vestar. "As Vestar's third drug to enter the clinic, MiKasome also represents an important component of the company's strategy to commercialize a broad product portfolio," he added.
 Amikacin is an aminoglycoside antibiotic that is employed against many infections. Its use, however, has been limited by a high degree of toxicity, including kidney damage and hearing loss at effective doses. Vestar's liposomal technology has been shown to reduce such limiting side effects with other drugs, thereby enabling clinicians to achieve improved efficacy without toxicity.
 Vestar, headquartered in San Dimas, Calif., develops, manufactures and markets pharmaceuticals to treat patients with cancer and serious infections, including AIDS. Since 1989, Vestar has been marketing AmBisome(R) in Europe, to treat systemic fungal infections. DaunoXome(R) is Vestar's second major product, for the treatment of AIDS associated Kaposi's sarcoma. Among the company's proprietary drug delivery technologies are liposomes to encapsulate pharmaceuticals, and lipid prodrug technology for the development of orally active compounds.
 -0- 7/7/93
 /CONTACT: Michael E. Hart, chief financial officer of Vestar, Inc., 909-394-4119; Marcia A. Kean, executive vice president of Feinstein Partners Inc., 617-577-8110, for Vestar/
 (VSTR)


CO: Vestar, Inc. ST: California IN: MTC SU:

DJ -- NE002 -- 8945 07/07/93 09:05 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jul 7, 1993
Words:304
Previous Article:URETHANE TECHNOLOGIES AGREES TO SUPPLY FLAT-FREE AIRLESS BICYCLE TIRE TECHNOLOGY TO TWO ASIAN MANUFACTURERS
Next Article:SUNOCO'S NEW FLEET CARD SOON TO BE AVAILABLE
Topics:


Related Articles
VESTAR R&D UPDATE AT ALEX BROWN HEALTH CARE CONFERENCE
VESTAR'S MIKASOME ACTIVE AGAINST DRUG-RESISTANT TUBERCULOSIS; ONE OF FOUR NEW PRODUCTS HEADED TO CLINIC, VESTAR ANNOUNCES
VESTAR'S AMBISOME GAINS FULL MARKETING APPROVAL IN THE NETHERLANDS
VESTAR'S AMBISOME GAINS FULL MARKETING APPROVAL IN GREECE
FDA'S ONCOLOGY ADVISORY COMMITTEE REVIEWS CLINICAL DATA ON VESTAR'S DAUNOXOME FOR TREATMENT OF KAPOSI'S SARCOMA
VESTAR REPORTS SECOND QUARTER 1993 RESULTS; REVENUES UP 34 PERCENT AS R&D AND MARKETING EXPENDITURES ACCELERATE
JANE L. DELGADO, PH.D. JOINS VESTAR'S BOARD
NeXstar Begins Third Phase II Trial for MiKasome
Rib-X Granted Key Antibiotic Patent in China.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters